BRAF
Summary: This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome. [provided by RefSeq, Aug 2017].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| B-Raf proto-oncogene, serine/threonine kinase | MIM:164757 | Ensembl:ENSG00000157764 | HGNC:HGNC:1097 | PA25408 | 7q34 |
GO terms in BRAF
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| BP | IBA | GO:0000165 | MAPK cascade |
| BP | TAS | GO:0000165 | MAPK cascade |
| BP | IEA | GO:0000186 | activation of MAPKK activity |
| BP | IDA | GO:0006468 | protein phosphorylation |
| BP | TAS | GO:0009887 | animal organ morphogenesis |
| BP | IMP | GO:0010628 | positive regulation of gene expression |
| BP | IDA | GO:0010828 | positive regulation of glucose transmembrane transport |
| BP | IDA | GO:0033138 | positive regulation of peptidyl-serine phosphorylation |
| BP | IDA | GO:0043066 | negative regulation of apoptotic process |
| BP | IDA | GO:0070374 | positive regulation of ERK1 and ERK2 cascade |
| BP | IMP | GO:0070413 | trehalose metabolism in response to stress |
| BP | IDA | GO:0071277 | cellular response to calcium ion |
| BP | IDA | GO:0090150 | establishment of protein localization to membrane |
| CC | IEA | GO:0005634 | nucleus |
| CC | IBA | GO:0005739 | mitochondrion |
| CC | IBA | GO:0005829 | cytosol |
| CC | IDA | GO:0005829 | cytosol |
| CC | TAS | GO:0005829 | cytosol |
| CC | IBA | GO:0005886 | plasma membrane |
| CC | TAS | GO:0005886 | plasma membrane |
| CC | IDA | GO:0043231 | intracellular membrane-bounded organelle |
| MF | IDA | GO:0004672 | protein kinase activity |
| MF | IBA | GO:0004674 | protein serine/threonine kinase activity |
| MF | IDA | GO:0004674 | protein serine/threonine kinase activity |
| MF | IDA | GO:0005509 | calcium ion binding |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0005524 | ATP binding |
| MF | IPI | GO:0031267 | small GTPase binding |
| MF | IPI | GO:0042802 | identical protein binding |
Gene expression in normal tissue: BRAF
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in BRAF
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| pid | cd8tcrdownstreampathway | Downstream signaling in naïve CD8+ T cells |
| pid | cdc42_pathway | CDC42 signaling events |
| pid | erbb1_downstream_pathway | ErbB1 downstream signaling |
| pid | fak_pathway | Signaling events mediated by focal adhesion kinase |
| pid | mapktrkpathway | Trk receptor signaling mediated by the MAPK pathway |
| pid | mtor_4pathway | mTOR signaling pathway |
| pid | pdgfrbpathway | PDGFR-beta signaling pathway |
| pid | tcrraspathway | Ras signaling in the CD4+ TCR pathway |
| pid | vegfr1_2_pathway | Signaling events mediated by VEGFR1 and VEGFR2 |
| kegg | hsa04010 | MAPK signaling pathway - Homo sapiens (human) |
| kegg | hsa04012 | ErbB signaling pathway - Homo sapiens (human) |
| kegg | hsa04015 | Rap1 signaling pathway - Homo sapiens (human) |
| kegg | hsa04024 | cAMP signaling pathway - Homo sapiens (human) |
| kegg | hsa04062 | Chemokine signaling pathway - Homo sapiens (human) |
| kegg | hsa04068 | FoxO signaling pathway - Homo sapiens (human) |
| kegg | hsa04150 | mTOR signaling pathway - Homo sapiens (human) |
| kegg | hsa04270 | Vascular smooth muscle contraction - Homo sapiens (human) |
| kegg | hsa04510 | Focal adhesion - Homo sapiens (human) |
| kegg | hsa04650 | Natural killer cell mediated cytotoxicity - Homo sapiens (human) |
| kegg | hsa04720 | Long-term potentiation - Homo sapiens (human) |
| kegg | hsa04722 | Neurotrophin signaling pathway - Homo sapiens (human) |
| kegg | hsa04726 | Serotonergic synapse - Homo sapiens (human) |
| kegg | hsa04730 | Long-term depression - Homo sapiens (human) |
| kegg | hsa04810 | Regulation of actin cytoskeleton - Homo sapiens (human) |
| kegg | hsa04910 | Insulin signaling pathway - Homo sapiens (human) |
| kegg | hsa04914 | Progesterone-mediated oocyte maturation - Homo sapiens (human) |
| kegg | hsa04934 | Cushing,s syndrome - Homo sapiens (human) |
| kegg | hsa05034 | Alcoholism - Homo sapiens (human) |
| kegg | hsa05160 | Hepatitis C - Homo sapiens (human) |
| kegg | hsa05200 | Pathways in cancer - Homo sapiens (human) |
| kegg | hsa05205 | Proteoglycans in cancer - Homo sapiens (human) |
| kegg | hsa05210 | Colorectal cancer - Homo sapiens (human) |
| kegg | hsa05211 | Renal cell carcinoma - Homo sapiens (human) |
| kegg | hsa05212 | Pancreatic cancer - Homo sapiens (human) |
| kegg | hsa05213 | Endometrial cancer - Homo sapiens (human) |
| kegg | hsa05214 | Glioma - Homo sapiens (human) |
| kegg | hsa05215 | Prostate cancer - Homo sapiens (human) |
| kegg | hsa05216 | Thyroid cancer - Homo sapiens (human) |
| kegg | hsa05218 | Melanoma - Homo sapiens (human) |
| kegg | hsa05219 | Bladder cancer - Homo sapiens (human) |
| kegg | hsa05220 | Chronic myeloid leukemia - Homo sapiens (human) |
| kegg | hsa05221 | Acute myeloid leukemia - Homo sapiens (human) |
| kegg | hsa05223 | Non-small cell lung cancer - Homo sapiens (human) |
| kegg | hsa05224 | Breast cancer - Homo sapiens (human) |
| kegg | hsa05225 | Hepatocellular carcinoma - Homo sapiens (human) |
| kegg | hsa05226 | Gastric cancer - Homo sapiens (human) |
| pharmgkb | PA165959425 | Pathway_PA165959425 |
| pharmgkb | PA165959584 | Sorafenib Pharmacodynamics |
| pharmgkb | PA165980050 | Vemurafenib Pathway, Pharmacodynamics |
| pharmgkb | PA165980050 | update your name in edit mode |
| netpath | Pathway_EGFR1 | EGFR1 |
| smpdb | SMP00320 | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine |
| smpdb | SMP00321 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine |
| wikipathways | WP185 | Integrin-mediated Cell Adhesion |
| wikipathways | WP2032 | Human Thyroid Stimulating Hormone (TSH) signaling pathway |
| wikipathways | WP2261 | Signaling Pathways in Glioblastoma |
| wikipathways | WP23 | B Cell Receptor Signaling Pathway |
| wikipathways | WP2355 | Corticotropin-releasing hormone signaling pathway |
| wikipathways | WP2512 | Integrated Lung Cancer Pathway |
| wikipathways | WP2571 | Polycystic Kidney Disease Pathway |
| wikipathways | WP2828 | Bladder Cancer |
| wikipathways | WP306 | Focal Adhesion |
| wikipathways | WP3676 | BDNF-TrkB Signaling |
| wikipathways | WP382 | MAPK Signaling Pathway |
| wikipathways | WP3929 | Chemokine signaling pathway |
| wikipathways | WP3931 | ESC Pluripotency Pathways |
| wikipathways | WP4155 | Endometrial cancer |
| wikipathways | WP4205 | MET in type 1 papillary renal cell carcinoma |
| wikipathways | WP4216 | Chromosomal and microsatellite instability in colorectal cancer |
| wikipathways | WP422 | MAPK Cascade |
| wikipathways | WP437 | EGF-EGFR Signaling Pathway |
| wikipathways | WP51 | Regulation of Actin Cytoskeleton |
| wikipathways | WP615 | Senescence and Autophagy in Cancer |
| wikipathways | WP712 | Estrogen signaling pathway |
| wikipathways | WP722 | Serotonin HTR1 Group and FOS Pathway |
| wikipathways | WP734 | Serotonin Receptor 4-6-7 and NR3C Signaling |
| reactome | R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission |
| reactome | R-HSA-112315 | Transmission across Chemical Synapses |
| reactome | R-HSA-112316 | Neuronal System |
| reactome | R-HSA-1295596 | Spry regulation of FGF signaling |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-1643685 | Disease |
| reactome | R-HSA-166520 | Signaling by NTRKs |
| reactome | R-HSA-169893 | Prolonged ERK activation events |
| reactome | R-HSA-170968 | Frs2-mediated activation |
| reactome | R-HSA-170984 | ARMS-mediated activation |
| reactome | R-HSA-187037 | Signaling by NTRK1 (TRKA) |
| reactome | R-HSA-187687 | Signalling to ERKs |
| reactome | R-HSA-187706 | Signalling to p38 via RIT and RIN |
| reactome | R-HSA-190236 | Signaling by FGFR |
| reactome | R-HSA-438064 | Post NMDA receptor activation events |
| reactome | R-HSA-442742 | CREB phosphorylation through the activation of Ras |
| reactome | R-HSA-442755 | Activation of NMDA receptor and postsynaptic events |
| reactome | R-HSA-5654726 | Negative regulation of FGFR1 signaling |
| reactome | R-HSA-5654727 | Negative regulation of FGFR2 signaling |
| reactome | R-HSA-5654732 | Negative regulation of FGFR3 signaling |
| reactome | R-HSA-5654733 | Negative regulation of FGFR4 signaling |
| reactome | R-HSA-5654736 | Signaling by FGFR1 |
| reactome | R-HSA-5654738 | Signaling by FGFR2 |
| reactome | R-HSA-5654741 | Signaling by FGFR3 |
| reactome | R-HSA-5654743 | Signaling by FGFR4 |
| reactome | R-HSA-5663202 | Diseases of signal transduction |
| reactome | R-HSA-5673000 | RAF activation |
| reactome | R-HSA-5673001 | RAF/MAP kinase cascade |
| reactome | R-HSA-5674135 | MAP2K and MAPK activation |
| reactome | R-HSA-5674499 | Negative feedback regulation of MAPK pathway |
| reactome | R-HSA-5675221 | Negative regulation of MAPK pathway |
| reactome | R-HSA-5683057 | MAPK family signaling cascades |
| reactome | R-HSA-5684996 | MAPK1/MAPK3 signaling |
| reactome | R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants |
| reactome | R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants |
| reactome | R-HSA-6802949 | Signaling by RAS mutants |
| reactome | R-HSA-6802952 | Signaling by BRAF and RAF fusions |
| reactome | R-HSA-6802955 | Paradoxical activation of RAF signaling by kinase inactive BRAF |
| reactome | R-HSA-6802957 | Oncogenic MAPK signaling |
| reactome | R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases |
| reactome | R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD446 | LY 2183240 | 4 |
| iGMDRD498 | GW441756X | 1 |
| iGMDRD361 | 5Z-7-Oxozeaenol | 3 |
| iGMDRD599 | Salermide | 6 |
| iGMDRD559 | TAK-733 | 1 |
| iGMDRD494 | Neopeltolide | 1 |
| iGMDRD354 | Midostaurin | 1 |
| iGMDRD100 | Zebularine | 2 |
| iGMDRD692 | SB590885 | 6 |
| iGMDRD291 | AC1NS4S0 | 1 |
| iGMDRD640 | CAY10618 | 1 |
| iGMDRD268 | Cerulenin | 2 |
| iGMDRD480 | KU0060648 | 2 |
| iGMDRD138 | PX 12 | 1 |
| iGMDRD852 | BRD-K35604418 | 1 |
| iGMDRD862 | BRD-K94991378 | 1 |
| iGMDRD134 | Sorafenib | 9 |
| iGMDRD440 | Nutlin-3A | 1 |
| iGMDRD309 | 17AAG | 2 |
| iGMDRD727 | Alpelisib | 1 |
| iGMDRD85 | Ursolic acid | 3 |
| iGMDRD536 | PLX-4720 | 18 |
| iGMDRD57 | Chloropentafluorobenzene | 3 |
| iGMDRD307 | Manumycin A | 2 |
| iGMDRD512 | nutlin 3 | 5 |
| iGMDRD410 | Ko-143 | 2 |
| iGMDRD792 | Cetuximab | 15 |
| iGMDRD424 | Tamatinib | 5 |
| iGMDRD32 | Metformin | 1 |
| iGMDRD500 | Cobimetinib | 91 |
| iGMDRD652 | UNC0638 | 1 |
| iGMDRD837 | Bevacizumab | 1 |
| iGMDRD882 | CIL41 | 4 |
| iGMDRD3 | PD-173074 | 1 |
| iGMDRD967 | Panitumumab | 21 |
| iGMDRD544 | Vismodegib (GDC-0449) | 1 |
| iGMDRD269 | Purmorphamine | 2 |
| iGMDRD695 | FR-180204 | 2 |
| iGMDRD1016 | THZ-2-49 | 1 |
| iGMDRD785 | XMD15-27 | 1 |
| iGMDRD514 | ERK inhibitor | 4 |
| iGMDRD6 | AM-580 | 4 |
| iGMDRD88 | AICA ribonucleotide | 1 |
| iGMDRD434 | BMS-536924 | 2 |
| iGMDRD481 | Dactolisib | 2 |
| iGMDRD333 | MEK Inhibitor | 17 |
| iGMDRD231 | Importazole | 4 |
| iGMDRD61 | Kinetin riboside | 3 |
| iGMDRD748 | PHA-665752 | 1 |
| iGMDRD470 | Trametinib | 247 |
| iGMDRD409 | Saracatinib | 1 |
| iGMDRD12 | Bicalutamide | 1 |
| iGMDRD670 | ML 210 | 4 |
| iGMDRD483 | SCH-529074 | 6 |
| iGMDRD133 | Lapatinib | 1 |
| iGMDRD888 | Compound 44 | 7 |
| iGMDRD851 | BRD-K34222889 | 1 |
| iGMDRD838 | BGB659 | 2 |
| iGMDRD23 | Gossypol | 2 |
| iGMDRD247 | Blebbistatin | 4 |
| iGMDRD920 | HSP90 inhibitor | 2 |
| iGMDRD207 | Capsaicin | 3 |
| iGMDRD816 | anti-EGFR mAbs | 3 |
| iGMDRD226 | ML006 | 4 |
| iGMDRD468 | AZ628 | 4 |
| iGMDRD187 | BRD9876 | 1 |
| iGMDRD698 | Neratinib | 4 |
| iGMDRD352 | PD-0325901 | 3 |
| iGMDRD237 | ABT-751 | 3 |
| iGMDRD154 | NSC23766 | 5 |
| iGMDRD719 | IOX2 | 2 |
| iGMDRD276 | AS 605240 | 1 |
| iGMDRD871 | BRD6368 | 1 |
| iGMDRD367 | Ro 28-1675 | 1 |
| iGMDRD147 | Prima-1 | 5 |
| iGMDRD534 | BRD1429 | 4 |
| iGMDRD264 | Bryostatin 1 | 1 |
| iGMDRD293 | Bleomycin | 1 |
| iGMDRD137 | Indisulam | 3 |
| iGMDRD265 | Dacarbazine | 1 |
| iGMDRD311 | Dacinostat | 2 |
| iGMDRD213 | SMR000068650 | 4 |
| iGMDRD608 | Refametinib | 9 |
| iGMDRD201 | SKI II | 2 |
| iGMDRD163 | all trans Retinoic Acid | 1 |
| iGMDRD401 | Afatinib | 4 |
| iGMDRD235 | SNS-032 | 1 |
| iGMDRD83 | Capecitabine | 1 |
| iGMDRD136 | Nutlin-3 | 1 |
| iGMDRD554 | CHEMBL1434137 | 6 |
| iGMDRD313 | Axitinib | 1 |
| iGMDRD229 | B02 | 4 |
| iGMDRD387 | CHIR-99021 | 3 |
| iGMDRD659 | Avagacestat (BMS-708163) | 1 |
| iGMDRD239 | Dasatinib | 4 |
| iGMDRD180 | CDK2/4 inhibitor | 2 |
| iGMDRD596 | Vemurafenib | 346 |
| iGMDRD332 | A-770041 | 1 |
| iGMDRD577 | BIX01294 | 4 |
| iGMDRD570 | MLS006011051 | 1 |
| iGMDRD131 | Erlotinib | 1 |
| iGMDRD509 | NVP-BHG712 | 1 |
| iGMDRD491 | TAE-684 | 1 |
| iGMDRD613 | CHEMBL258148 | 3 |
| iGMDRD109 | Gefitinib | 1 |
| iGMDRD573 | GSK-1904529A | 1 |
| iGMDRD782 | DC-45-A2 | 6 |
| iGMDRD318 | PAC-1 | 1 |
| iGMDRD870 | BRD63610 | 2 |
| iGMDRD178 | MG-132 | 1 |
| iGMDRD486 | Tosedostat | 1 |
| iGMDRD858 | BRD-K71935468 | 1 |
| iGMDRD614 | Dabrafenib | 371 |
| iGMDRD456 | Crizotinib | 2 |
| iGMDRD299 | ICL 670 | 4 |
| iGMDRD701 | NVP-AUY922 | 2 |
| iGMDRD232 | FTI-277 | 2 |
| iGMDRD80 | Irinotecan | 1 |
| iGMDRD472 | PF-562271 | 2 |
| iGMDRD505 | Pevonedistat | 6 |
| iGMDRD300 | Tozasertib | 2 |
| iGMDRD935 | JQ12 | 1 |
| iGMDRD353 | PD0325901 | 5 |
| iGMDRD990 | PL.DI | 1 |
| iGMDRD271 | Brefeldin A | 4 |
| iGMDRD68 | Paclitaxel | 1 |
| iGMDRD389 | SB525334 | 1 |
| iGMDRD415 | LE-135 | 4 |
| iGMDRD504 | Obatoclax | 2 |
| iGMDRD381 | Rucaparib | 1 |
| iGMDRD107 | Valdecoxib | 1 |
| iGMDRD2 | PK-11195 | 2 |
| iGMDRD152 | 179324-69-7 | 1 |
| iGMDRD860 | BRD-K90370028 | 1 |
| iGMDRD394 | BX-795 | 1 |
| iGMDRD443 | Linifanib | 1 |
| iGMDRD420 | Leucascandrolide A | 4 |
| iGMDRD779 | PRL-3 Inhibitor I | 4 |
| iGMDRD781 | Sirolimus | 5 |
| iGMDRD899 | EGFR TK inhibitor | 6 |
| iGMDRD188 | Piperlongumine | 1 |
| iGMDRD338 | MEK Inhibitor in EGFR mutant | 1 |
| iGMDRD399 | Selumetinib | 13 |
| iGMDRD190 | Nilotinib | 1 |
| iGMDRD41 | Imatinib | 1 |
| iGMDRD874 | BRD8958 | 4 |
| iGMDRD513 | BML-259 | 4 |
| iGMDRD449 | RO4987655 | 2 |
| iGMDRD983 | PI3K pathway inhibitor | 5 |
| iGMDRD117 | Docetaxel | 1 |
| iGMDRD284 | Palbociclib | 1 |
| iGMDRD801 | 2,4-dideoxy-DC-45-A2 | 2 |
| iGMDRD44 | Temozolomide | 1 |
| iGMDRD461 | VX-11e | 2 |
| iGMDRD341 | Triacsin c | 3 |
| iGMDRD605 | AZD6482 | 1 |
| iGMDRD511 | CHEMBL399379 | 4 |
| iGMDRD248 | BRD4354 | 4 |
| iGMDRD324 | CI-1040 | 5 |
| iGMDRD532 | Olaparib | 4 |
| iGMDRD520 | Pictilisib | 1 |
| iGMDRD150 | RITA | 1 |
| iGMDRD1036 | X17AAG | 1 |
| iGMDRD327 | LBH-589 | 1 |
| iGMDRD339 | MEK Inhibitor enhanced radioiodine uptake | 1 |
| iGMDRD839 | BRAF inhibitor | 29 |
| iGMDRD286 | Nsc 632839 | 1 |
| iGMDRD968 | Pan-RAF inhibitor | 10 |
| iGMDRD329 | Merck60 | 1 |
| iGMDRD561 | ABT-263 | 1 |
| iGMDRD245 | FH535 | 2 |
| iGMDRD766 | LY3009120 | 1 |
| iGMDRD705 | Nakiterpiosin | 1 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in BRAF
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.